Previous 10 | Next 10 |
Owens Corning Inc New (OC) is expected to report $2.82 for Q4 2023 Getty Realty Corporation (GTY) is expected to report $0.56 for Q4 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q2 2024 Nexien BioPharma Inc (NXEN) is expected to report for Q2 2024 Ayt...
2024-02-13 17:35:43 ET Major earnings expected after the bell on Wednesday include: Cisco Systems ( CSCO ) Energy Transfer LP ( ET ) Accidental Petroleum Corporation ( OXY ) Twilio ( TWLO ) Albemarle Corporation ( ALB ) Read the full article...
2024-02-13 17:20:44 ET More on Aytu BioScience Seeking Alpha’s Quant Rating on Aytu BioScience Historical earnings data for Aytu BioScience Financial information for Aytu BioScience Read the full article on Seeking Alpha For further details see...
DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December...
DENVER, CO / ACCESSWIRE / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings with investors...
2023-11-15 11:44:02 ET More on Markets UBS highlights 14 stocks on its list of high-conviction names Global X says AI, cybersecurity among four key themes for 2024 Cathie Wood's ARK Invest launches crypto ETFs in partnership with 21Shares Producer Price Index...
2023-11-14 19:30:27 ET Aytu BioPharma, Inc. (AYTU) Q1 2024 Earnings Conference Call November 14, 2023 04:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Naz Rahman - Maxim Group Prese...
2023-11-14 16:28:51 ET More on Aytu BioScience Aytu BioPharma, Inc. (AYTU) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Aytu BioScience Historical earnings data for Aytu BioScience Financial information for Aytu BioScience F...
Q1 2024 Adjusted EBITDA of $2.2 million Rx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024 Q1 2024 ADHD net revenue up 31% compared to Q1 2023 $20.0 million cash balance at September 30, 2023 Company to host conference call today at 4:30pm E...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
News, Short Squeeze, Breakout and More Instantly...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...